Literature DB >> 25577659

Prosthetic mitral valve thrombosis in pregnancy: from thrombolysis to anticoagulation.

Gonçalo Cardoso1, Carlos Aguiar2, Maria João Andrade2, Lino Patrício3, Isabel Freire4, Fátima Serrano5, Rui Anjos6, Miguel Mendes2.   

Abstract

INTRODUCTION: Pregnant women with mechanical prosthetic heart valves are at increased risk for valve thrombosis. Management decisions for this life-threatening complication are complex. Open-heart surgery has a very high risk of maternal mortality and fetal loss. Bleeding and embolic risks associated with thrombolytic agents, the limited efficacy of thrombolysis in certain subgroups, and a lack of experience in the setting of pregnancy raise important concerns. CASE REPORT: We report a case of mitral prosthetic valve thrombosis in early pregnancy, which was successfully treated with streptokinase. Ten years later, the same patient had an uneventful pregnancy, throughout which acenocoumarol was maintained.
CONCLUSION: With this case we review the prevention (with oral anticoagulant therapy) and treatment of prosthetic valve thrombosis during pregnancy, which is important for both obstetrician and cardiologist.
Copyright © 2014 Sociedade Portuguesa de Cardiologia. Published by Elsevier España. All rights reserved.

Entities:  

Keywords:  Anticoagulation; Anticoagulação; Gravidez; Pregnancy; Thrombolysis; Trombose de prótese; Trombólise; Valve thrombosis

Mesh:

Substances:

Year:  2015        PMID: 25577659     DOI: 10.1016/j.repc.2014.09.007

Source DB:  PubMed          Journal:  Rev Port Cardiol        ISSN: 0870-2551            Impact factor:   1.374


  2 in total

1.  Prosthetic heart valve thrombosis in pregnancy: a case series on acute management.

Authors:  S Foolchand; H Ramnarain
Journal:  Cardiovasc J Afr       Date:  2021-05-04       Impact factor: 1.167

Review 2.  Pre-conception counselling for key cardiovascular conditions in Africa: optimising pregnancy outcomes.

Authors:  Liesl Zühlke; Letitia Acquah
Journal:  Cardiovasc J Afr       Date:  2016 Mar-Apr       Impact factor: 1.167

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.